Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR)‘s stock had its “buy” rating reiterated by equities researchers at Needham & Company LLC in a research note issued to investors on Thursday. They currently have a $26.00 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $36.00. Needham & Company LLC’s price target indicates a potential upside of 169.43% from the stock’s current price.

ALDR has been the subject of a number of other reports. Zacks Investment Research upgraded Alder BioPharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price target for the company in a research note on Tuesday, July 11th. Credit Suisse Group cut Alder BioPharmaceuticals from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $30.00 to $17.00 in a research note on Wednesday, June 28th. Wells Fargo & Company reaffirmed an “outperform” rating and set a $51.00 target price on shares of Alder BioPharmaceuticals in a research report on Wednesday, June 28th. ValuEngine lowered Alder BioPharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, June 29th. Finally, Aegis reaffirmed a “buy” rating and set a $41.00 target price on shares of Alder BioPharmaceuticals in a research report on Wednesday, July 5th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company’s stock. Alder BioPharmaceuticals presently has a consensus rating of “Buy” and an average target price of $32.92.

Shares of Alder BioPharmaceuticals (NASDAQ ALDR) opened at 9.65 on Thursday. The stock has a 50 day moving average price of $12.14 and a 200 day moving average price of $18.37. Alder BioPharmaceuticals has a 1-year low of $9.15 and a 1-year high of $36.48. The firm’s market capitalization is $486.46 million.

Alder BioPharmaceuticals (NASDAQ:ALDR) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.48) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.67) by $0.19. The firm had revenue of $0.68 million during the quarter. During the same period last year, the firm earned ($0.79) EPS. The business’s revenue was up 518.2% compared to the same quarter last year. Equities research analysts anticipate that Alder BioPharmaceuticals will post ($6.27) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Alder BioPharmaceuticals, Inc. (ALDR) Given “Buy” Rating at Needham & Company LLC” was reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/08/10/alder-biopharmaceuticals-inc-aldr-given-buy-rating-at-needham-company-llc.html.

In other Alder BioPharmaceuticals news, Director Stephen M. Dow purchased 25,000 shares of the firm’s stock in a transaction on Tuesday, July 18th. The stock was purchased at an average cost of $10.00 per share, for a total transaction of $250,000.00. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. 10.60% of the stock is owned by company insiders.

A number of hedge funds have recently modified their holdings of ALDR. Russell Investments Group Ltd. acquired a new stake in shares of Alder BioPharmaceuticals during the fourth quarter worth $334,000. Norges Bank acquired a new stake in shares of Alder BioPharmaceuticals during the fourth quarter worth $5,453,000. Teachers Advisors LLC increased its stake in shares of Alder BioPharmaceuticals by 1.5% in the fourth quarter. Teachers Advisors LLC now owns 76,809 shares of the biopharmaceutical company’s stock worth $1,598,000 after buying an additional 1,171 shares during the last quarter. Macquarie Group Ltd. increased its stake in shares of Alder BioPharmaceuticals by 39.8% in the fourth quarter. Macquarie Group Ltd. now owns 140,489 shares of the biopharmaceutical company’s stock worth $2,922,000 after buying an additional 40,000 shares during the last quarter. Finally, Bank of Montreal Can increased its stake in shares of Alder BioPharmaceuticals by 3,047.2% in the first quarter. Bank of Montreal Can now owns 5,602 shares of the biopharmaceutical company’s stock worth $117,000 after buying an additional 5,424 shares during the last quarter. Hedge funds and other institutional investors own 82.44% of the company’s stock.

About Alder BioPharmaceuticals

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Analyst Recommendations for Alder BioPharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.